Reports Q2 revenue $270.7M, consensus $257.95M. “Waystar (WAY) recorded strong Q2 results, including 15% revenue growth, driven by AI-powered innovations, trusted client relationships, and compelling and real ROI for healthcare providers,” said Matt Hawkins, CEO. “Our execution and momentum enable us to raise full-year revenue and adjusted EBITDA guidance. Waystar also recently announced an agreement to acquire Iodine Software, a leader in AI-powered clinical intelligence, which we expect will expand our total addressable market, be accretive to our financial profile, and position us to deliver even greater value to clients and shareholders.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAY:
- Waystar Holding Corp.’s Strategic Acquisition of Iodine Software: A Buy Rating with Enhanced AI Capabilities and Market Expansion
- Waystar Holding Corp. Acquires Iodine Software for $1.25B
- Waystar sees Q2 revenue ~$271M, consensus $255.21M
- Waystar to acquire Iodine Software for $1.25B
- Waystar price target raised to $51 from $50 at Truist